Mesothelioma is an aggressive tumor with a poor prognosis. Histological diagnosis of mesothelioma using limited tissue samples can be challenging. Carbonic anhydrase IX (CAIX) is a transmembrane ...

Post-conference recap highlights direct anti-tumor effects in epithelial and non-epithelioid mesothelioma models, >90% tumor growth inhibition in vivo when TT-4 was combined with anti-PD-1, and ...

Patients with malignant pleural mesothelioma are diagnosed at advanced stages and have limited treatment options. Patients with coexpression of ERCC1 and RPM1 in tumor tissues exhibited significantly ...

MVdeltaC, a modified measles virus, targets tumor cells and activates the immune system, showing promise in preclinical studies for pleural mesothelioma. The FDA's orphan drug designation provides ...

Mesothelioma, a rare cancer that usually starts in the lining around the lungs, has long been thought of as a condition that affects older men—especially those who may have been exposed to asbestos ...

Mesothelioma is a rare and aggressive cancer linked to asbestos exposure, particularly the amosite and crocidolite types. It primarily affects the pleura (lining of the lungs) but can also develop in ...

The global multicenter Phase I trial of ISM6331 that is enrolling patients in China and the United States has advanced with the dosing of the first patient in this study for the treatment of ...

Dr. Hedy Kindler joins us on the podcast to discuss the latest update to the treatment of pleural mesothelioma guideline. She discusses the latest changes to the updated recommendations across topics ...